CLINICAL OBSERVATIONS ON THE USE OF NEW ANTI-VEGF DRUG, CONBERCEPT, IN AGE-RELATED MACULAR DEGENERATION THERAPY: A META-ANALYSIS

Chunmei Cui, Hong Lu Department of Ophthalmology, Beijing Chao-Yang Hospital, Beijing, China Purpose: Conbercept is a IEC Power Adapters new anti-vascular endothelial growth factor (VEGF) drug approved for the treatment of age-related macular degeneration (AMD).Although this novel drug has been widely used in clinic, unlike other anti-VEGF drugs, v